Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial
Robert I. Haddad(Georgetown University), Thomas Gauler, Jan B. Vermorken(University of Antwerp), Daniel Rauch(Washington University in St. Louis), J. Guigay(Centre Antoine Lacassagne), Bohuslav Melichar(Palacký University Olomouc), Makoto Tahara(National Cancer Center Hospital East), Sylvie Zanetta-Devauges(Centre Georges François Leclerc), Jérôme Fayette(Université Claude Bernard Lyon 1), Ulisses Ribaldo Nicolau(AC Camargo Hospital), Frédéric Rolland(Institut de Cancérologie de l'Ouest), Lisa Licitra(University of Milan), Luciano de Souza Viana(Hospital de Câncer de Barretos), Ulrich Keilholz(German Cancer Research Center), Lionnel Geoffrois(Institut de Cancérologie de Lorraine), Eleftherios Zografos, Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), Yuan Geng, Jean-Pascal Machiels(Cliniques Universitaires Saint-Luc), Paul M. Clément(Universitair Ziekenhuis Leuven), Gabriela Kornek(Medical University of Vienna), Ezra E.W. Cohen(Moores Cancer Center)
Cited by 10
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994